Despite the steep increase in new pharmaceutical products, small-molecule oral solid dosage products are still in high demand. In addition, companies are also looking more at the opportunities presented to the OSD market by reformulating using new technology to extend product lifecycles.
The ideal dosage form should have broad applicability, which is why tablets and capsules are still on-trend. Using tablets or capsules means you can achieve many different release profiles, including immediate, prolonged, and delayed release, orally disintegrating tablets, and fixed-dose combinations. Consequently, there still remains a lot of opportunity for companies across the market.
To help keep up with this demand, it is becoming increasingly important for pharmaceutical companies to partner with a CDMO – during the early development stages – with extensive knowledge of formulation development. Drug delivery innovation is becoming critical across the contract service space as pharma sponsors ultimately rely heavily on CDMOs to help them get these products to market.